# Ambys Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ambys-medicines

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.ambys.com
- Total disclosed funding: $107M
- Latest round: Series A (Dec 21, 2021)
- Investors on record: 7

## About

Ambys Medicines, Inc. is a biotechnology company focused on developing innovative cell therapies for liver diseases, addressing significant unmet medical needs in this field.Founded in 2016 and based in South San Francisco, US, Ambys Medicines, Inc. specializes in liver cell therapy. The company has successfully raised funding mainly through two rounds, with the latest being a Series A round in December 2021, which brought in USD 47 mn led by Third Rock Ventures and included investors such as Alexandria Venture Investments and Takeda Ventures. The CEO is Jeffrey Tong, and the company was founded by Markus Grompe.Ambys Medicines focuses on liver cell therapy, aiming to develop treatments designed to address a range of liver diseases. The company is working to advance its proprietary platform for liver cell therapies, which has the potential to significantly impact patient outcomes in liver disease management.Ambys Medicines has not publicly disclosed specific revenue figures. However, the company generates funding through its investment rounds aimed at advancing its research and development initiatives in liver cell therapy.Following the Series A funding round completed on December 21, 2021, Ambys Medicines intends to utilize the USD 47 mn raised to further the development of its liver cell therapy platform. This investment will support the design and launch of new therapeutic products aimed at treating various liver conditions. The company is also exploring expansion opportunities into new markets to reach a broader patient population affected by liver diseases.

## Funding rounds

- Series A, Dec 21, 2021, $47M — Schroders Capital, Alexandria Venture Investments, Third Rock Ventures, Takeda Ventures, Laurion Capital Management, Smilegate Investment
- Series A, Aug 8, 2018, $60M — Third Rock Ventures, Takeda Pharmaceutical

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Takeda Pharmaceutical — Series A
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Laurion Capital Management — Series A
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A